Omar Hamze, MD
Nephrology · Memphis, TNNPI 1437148293
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $70,922 of the $89,975 with a category attached, or 78.8%. 30 manufacturers reported payments, led by AstraZeneca at 33.8% of the total. Reporting peaked in 2022 at $26,920 and has fallen 86.6% since, to $3,613 in 2025. Among nephrology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 626 payments — averaging $143.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$30K
- Fresenius USA Marketing, Inc.$17K
- Bayer$15K
- Vifor Pharma, Inc.$9K
- Otsuka America Pharmaceutical, Inc.$7K
- Boehringer Ingelheim$3K
- plus $8K from 24 others
What the payments were for
- Consulting fees$3,0653%
- Speaking & faculty fees$70,92279%
- Travel & lodging$9551%
- Food & beverage$14,03416%
- Education$1,0001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 113 | $30,413 |
| Fresenius USA Marketing, Inc. | 77 | $17,208 |
| Bayer | 74 | $14,814 |
| Vifor Pharma, Inc. | 50 | $9,020 |
| Otsuka America Pharmaceutical, Inc. | 71 | $6,859 |
| Boehringer Ingelheim | 19 | $3,248 |
| Lilly USA, LLC | 4 | $2,334 |
| Aurinia Pharma U.S., Inc. | 40 | $1,152 |
| Amgen(2 entities) | 27 | $1,136 |
| Travere Therapeutics, Inc. | 44 | $820 |
| Ardelyx, Inc. | 21 | $556 |
| OPKO Pharmaceuticals, LLC | 26 | $479 |
| Calliditas Therapeutics US Inc. | 11 | $306 |
| Medtronic | 2 | $250 |
| Novartis | 9 | $238 |
| GSK | 8 | $156 |
| Nxstage Medical, Inc. | 1 | $135 |
| Bard Peripheral Vascular, Inc. | 1 | $119 |
| Johnson & Johnson | 1 | $119 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $96 |
| Recor Medical Inc | 6 | $93 |
| Vantive US Healthcare LLC | 1 | $77 |
| Mallinckrodt Hospital Products Inc. | 4 | $63 |
| Akebia Therapeutics Inc | 3 | $55 |
| Shield Therapeutics Inc | 3 | $53 |
| Cormedix Inc. | 2 | $53 |
| Sanofi | 2 | $47 |
| Mallinckrodt Enterprises LLC | 2 | $34 |
| Arbor Pharmaceuticals, Inc. | 2 | $30 |
| AbbVie | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$18,477
- Velphoro$16,087
- Kerendia$13,901
- FARXIGA$10,719
- Veltassa$8,120
- JYNARQUE$5,776
- JARDIANCE$4,533
- Parsabiv$500
- ELLIPSYS VASCULAR ACCESS SYSTEM$250
- LIBERTY SELECT CYCLER$135
- NXSTAGE SYSTEM ONE$135
- TARPEYO$121
- INVOKANA$119
- LUPKYNIS$117
- Tavneos$108
How this compares
$89,975 in reported general payments places this provider in the 95th percentile of 229 nephrology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 40 | $139,315 |
| FarxigaDapagliflozin Propanediol | 125 | $89,954 |
| JardianceEmpagliflozin | 66 | $44,756 |
| LokelmaSodium Zirconium Cyclosilicate | 47 | $39,366 |
| KerendiaFinerenone | 37 | $38,357 |
| VeltassaPatiromer Calcium Sorbitex | 19 | $35,068 |
| Sevelamer Carbonate | 119 | $17,827 |
| Cinacalcet Hcl | 11 | $3,327 |
| Losartan Potassium | 407 | $3,109 |
| Calcium Acetate | 43 | $2,684 |
| Bumetanide | 106 | $2,479 |
| Calcitriol | 114 | $2,183 |
| Hydralazine Hcl | 118 | $1,879 |
| ProsolParenteral Amino Acid 20% No.1 | 14 | $1,774 |
| Clonidine | 19 | $1,564 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $17,208 | $139,31540 claims |
| AstraZenecaFarxiga, Lokelma | $30,413 | $129,319172 claims |
| Boehringer IngelheimJardiance | $3,248 | $44,75666 claims |
| BayerKerendia | $14,814 | $38,35737 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 229 nephrology providers in Tennessee.
Other nephrology in Memphis
- Omar DavisMemphis$70K
- Natarsha GrantMemphis$53K
- Marc StegmanMemphis$41K
- Robert CanadaMemphis$20K
- Minesh PathakMemphis$14K
- Miklos MolnarMemphis$12K
- Wael HusseinMemphis$10K
- Sanjeev MittalMemphis$9K
- Vasanthi BalaramanMemphis$8K
- Mark Abi NaderMemphis$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.